Echocardiography illustrates a convenient and noninvasive tool for measuring cardiac output (CO) changes after administration of sedative drugs, but it is unknown in camelids practice. The aim of present study was to investigate echocardiographic effects of intravenous (IV) injection of medetomidine and xylazine in camel calves. Twenty apparently healthy immature male one-humped camel calves () were divided into four groups (five animals in each treatment). Medetomidine and xylazine were injected into the left jugular vein at two different doses of 10.00 and 20.00 μg kg and 0.20 and 0.40 mg kg, respectively. Effects on some selected echocardiographic parameters were recorded at different intervals, before drug administrations (baseline) and after 3, 60 and 120 min. Data were analyzed by repeated measure, ANOVA test, then relevance and significance were taken as ≤ 0.05. Significant decrease in fractional shortening percentage (FS%), ejection fraction percentage (EF%), stroke volume (SV), heart rate (HR) and subsequent CO were noticeable 3 min after drug administration in medetomidine high dose (MH), medetomidine low dose (ML) and xylazine high dose (XH) groups ( ≤ 0.05), furthermore at this time significant decrease in left ventricular mass (LVmass) and left ventricular systolic time intervals were seen in these groups, however, in xylazine low dose (XL) group, the lowest level of most echocardiographic parameters were detectable after 60 min. High dose IV injection of medetomidine was associated with significant decrease in most echocardiographic parameters without echocardiographic arrhythmia. Although, ML and XH groups had the same effects on echocardiographic indices but the intensity and duration were less than MH group.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094593 | PMC |
http://dx.doi.org/10.30466/vrf.2019.112347.2675 | DOI Listing |
Int J Drug Policy
January 2025
Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 1812 Ashland Avenue, 3rd Floor, Baltimore, MD 21205, USA.
Background: While the unregulated drug market has seen dramatic increases in fentanyl adulteration in the past decade, other adulterants have impacted the recent volatility of the drug supply. There has been recent documentation related to the presence of wound-associated substances; however, there is a lack of data showing the prevalence of these substances across unregulated drug market samples over time. The aim of this paper is to examine known and potential wound-associated agents' (xylazine, levamisole, medetomidine) prevalence in Maryland's unregulated drug supply.
View Article and Find Full Text PDFPLoS One
October 2024
Université-Lyon, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, Bron, France.
Background: The aim of our study was to test different anesthetic mixtures in order to identify the most suitable one for a surgical cardiac ischemia-reperfusion model in mice.
Methods: 1) Sixty four mice were submitted to one of the 6 combinations of ketamine or alfaxalone associated to xylazine, medetomidine or midazolam. Depth and quality of anesthesia were evaluated via 5 reflex scores.
ACS Chem Neurosci
November 2024
Warren Center for Neuroscience Drug Discovery and Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
Medetomidine is an FDA-approved α-adrenoreceptor (α-AR) agonist used as a veterinary sedative due to its analgesic, sedative, and anxiolytic properties. While it is marketed for veterinary use as a racemic mixture under the brand name Domitor, the pharmacologically active enantiomer, dexmedetomidine, is approved for sedation and analgesia in the hospital setting. Medetomidine has recently been detected in the illicit drug supply alongside fentanyl, xylazine, cocaine, and heroin, producing pronounced sedative effects that are not reversed by naloxone.
View Article and Find Full Text PDFJ Am Assoc Lab Anim Sci
November 2024
1Department of Comparative Medicine, Stanford University, Stanford, California; and.
Medetomidine/vatinoxan (Zenalpha®) is a novel anesthetic combination used as a sedative and analgesic in dogs. Vatinoxan minimizes adverse cardiopulmonary effects associated with medetomidine administration while preserving sedation and analgesia. In this study, we evaluated the clinical safety and efficacy of 3 dosage combinations of Zenalpha with ketamine and buprenorphine extended release (ER) as compared with xylazine with ketamine and buprenorphine-ER for anesthesia of C57BL/6J mice.
View Article and Find Full Text PDFVet Sci
April 2024
Department of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy.
(1) The main goals of general anesthesia include pain management and a safe anesthetic protocol for smooth recovery. In this retrospective study, we compared two anesthetic protocols for general anesthesia with isoflurane during emergency laparotomy: sedation with xylazine and the intraoperative infusion of lidocaine (X group) versus medetomidine as a preoperative sedation and intraoperative infusion (M group). (2) The medical records of horses who underwent emergency laparotomies between 2016 and 2023 were reviewed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!